Biogen makes a billion-dollar bet on Parkinson’s drugs
Biogen plans to spend more than $1B to access experimental Parkinson’s disease drugs and take an equity stake in their developer, Denali Therapeutics. Denali’s most advanced program, called DNL151, is included in the deal and set to enter late-stage clinical testing in 2021.
Biogen will also have an exclusive option to license two more Denali programs and right of first negotiation for another two unnamed programs.
